Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07720661

Comparative Outcomes of Mammary Artery Harvesting: Infection, Occlusion Rates and Thoracic Pain Assessment

The COMFORT Trial is a randomized controlled superiority trial comparing skeletonized (SK) versus non-skeletonized (non-SK) harvesting of the left internal mammary artery (LIMA) to left anterior descending artery (LAD) graft in patients undergoing isolated coronary artery bypass grafting (CABG).

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

The COMFORT trial is an international, multicentre, blinded, expertise-based randomized controlled trial evaluating two commonly used techniques for harvesting the left internal mammary artery (LIMA) during coronary artery bypass grafting (CABG): skeletonized and non-skeletonized (pedicled) harvesting.

Although skeletonized harvesting has been associated with reduced sternal wound complications and postoperative pain, concerns have emerged regarding its potential impact on graft patency and long-term cardiovascular outcomes. Existing evidence is largely derived from observational studies and post hoc analyses, and no adequately powered randomized trial has prospectively compared these techniques using systematic imaging-based graft assessment.

The COMFORT trial will enroll approximately 1,116 patients undergoing isolated CABG with a planned LIMA-to-LAD graft. Participants will be randomly assigned to undergo either skeletonized or non-skeletonized LIMA harvesting performed by surgeons experienced in both techniques. Participants and outcome assessors will remain blinded to treatment allocation.

Participants will undergo protocol-mandated coronary computed tomography angiography (CTA) at 1.5 years after surgery, with follow-up extending to 2 years. Independent blinded committees and a central CTA core laboratory will adjudicate imaging and clinical outcomes. In addition to graft assessment, the study will evaluate the effects of harvesting technique on cardiovascular outcomes, sternal wound complications, chronic postoperative pain, quality of life, and healthcare resource utilization.

The findings of COMFORT are expected to provide definitive evidence to guide surgical practice and inform future guidelines regarding the optimal method of internal mammary artery harvesting during CABG surgery.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 years or older
  • Undergoing isolated CABG surgery with median sternotomy and a planned LIMA-LAD graft
  • Provision of written informed consent

Exclusion criteria

  • Non-sternotomy surgical approach (e.g., minimally invasive, thoracotomy)
  • Emergency surgery (defined as surgery required within 24 hours of presentation)
  • History of prior sternotomy
  • Currently receiving systemic antibiotics or with an active bacterial infection at the time of surgery
  • History of chronic sternal pain prior to the index surgery
  • Known left subclavian artery stenosis (>50%)
  • Previous radiation therapy to the chest
  • Known allergy or contraindication to iodinated contrast media that cannot be managed with premedication
  • Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m² at baseline (relative contraindication to CTA contrast) as determined based on each centre's laboratory standard.
  • Known pregnancy or plans for pregnancy during the study period
  • Life expectancy less than 1.5 years due to non-cardiac conditions
  • Inability or unwillingness to comply with follow-up procedures including CTA at 1.5 years

Treatment and study plan

Skeletonized LIMA Harvesting

Procedure

Skeletonized (SK) harvesting of the left internal mammary artery (LIMA) to left anterior descending artery (LAD) graft: the LIMA is isolated without surrounding satellite veins, endothoracic fascia, and intercostal nerves

Non-Skeletonized LIMA Harvesting

Procedure

Non-skeletonized (non-SK) harvesting of the LIMA-LAD graft: the LIMA is harvested with surrounding satellite veins, endothoracic fascia, and intercostal nerves (standard pedicled technique)

Primary outcomes

  1. Graft Patency

    Time frame: 1.5 years after surgery

    Binary assessment of LIMA-LAD graft patency versus graft failure

Secondary outcomes

  1. MACE

    Time frame: 2 years after surgery

    The composite of cardiovascular mortality, myocardial infarction, or repeat revascularization

  2. Sternal Surgical Site Infection

    Time frame: 90 days after surgery

    The composite of sternal surgical site infection

  3. Sternal Chronic Postsurgical Pain

    Time frame: 90 days after surgery

    The composite of non-infected sternal chronic postsurgical pain

  4. LIMA-LAD Driven Repeat Revascularization or Occlusion

    Time frame: 2 years after surgery

    Any coronary revascularization procedure (PCI or CABG) targeting the LIMA-LAD graft territory, or occlusion of the LIMA-LAD graft revealed by clinically indicated coronary angiography or CTA

Study contacts

Contact information is provided by the study sponsor or research team.

Ingrid Copland

CONTACT

[email protected]

905-296-5754

Sponsors and collaborators

Lead sponsor

Hamilton Health Sciences Corporation

Other

Collaborators

  • Population Health Research Institute

Registry information

Official study title

COMFORT: Comparative Outcomes of Mammary Artery Harvesting: Infection, Occlusion Rates and Thoracic Pain Assessment

Acronym: COMFORT

Important dates

Study start
2026
Primary completion
2028
Study completion
2029
First posted
Jul 22, 2026
Registry last updated
Jul 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.